Wells Fargo maintains Alumis at Overweight, lowers price target to $18 from $25

Wells Fargo downgraded its price target for Alumis to $18 from $25, a 28% decrease, while maintaining an Overweight rating. The new target implies a 193.6% upside from the Nov 12 close of $6.13, according to the bank.

Original reporting
Published Nov 13, 2026, 4:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 4:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wells Fargo maintains Alumis at Overweight, lowers price target to $18 from $25 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The downgrade suggests a lower near‑term upside, prompting investors to reassess valuation.

02

Market read

Analyst rating change provides a fresh data point for traders monitoring the stock.

03

What to watch

Potential upcoming catalyst or market sentiment shift not reflected in the rating.

Relevance 7/10Novelty 6/10Timing: today

Background

Wells Fargo downgraded its rating on Alumis and reduced the price target from $25 to $18.

Market effects

Minimal impact on broader sector; analyst rating change affects only the specific micro‑cap.

Limited to investors tracking the stock; no regional effect.

None

Counterpoint

The price target cut may be overly pessimistic if the company’s fundamentals remain strong.

Key entities

  • Wells Fargo

    Issuer of the rating and price target change.

Related articles

$ALMSMed

Alumis Reports Q3 2026 Results, $94.9 Million Net Loss

Alumis reported Q3 2026 revenue of $1.9M and a net loss of $94.9M. Cash reserves totaled $431.3M, expected to last into Q4 2027. The company plans to submit an NDA for envudeucitinib in plaque psoriasis by Q4 2026, with positive Phase 3 data for scalp psoriasis. A Phase 2b trial in lupus did not meet primary endpoints, but a subgroup showed responses. Alumis will start a Phase 2 trial for A-005 in Parkinson's in 2027.

$ALMSHigh

Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates

ALUMIS INC. (ALMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Exhibit 99.1 ​ ​ Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates ​ – New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib’s differentiated clinical profile, including the hig

$ALMSHighAI 8/10

Alumis (ALMS) Faces Pressure After Clinical Results

Voya MI Dynamic Small Cap Fund reported that its overweight position in Alumis (ALMS) hurt performance due to disappointing clinical trial results. ALMS closed at $6.62 with a $883.74M market cap, up 25.38% over 52 weeks. The fund's Q3 2026 letter cited sector performance variations, with energy, tech, and healthcare outperforming.

$JNJMedAI 8/10

Johnson & Johnson reports at least 72% PASI 90

Johnson & Johnson (JNJ) reported that its oral psoriasis drug ICOTYDE maintained at least 72% PASI 90 response rates through week 112 in the Phase 3 ICONIC-LEAD trial. JNJ shares rose 0.40% to $257.50. Alumis (ALMS) is also developing a psoriasis drug, envudeucitinib, with a planned U.S. application in Q4 2026.